Uncomplicated UTIs: Antibiotics lasting over 7 days tied to adverse events - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Uncomplicated UTIs: Antibiotics lasting over 7 days tied to adverse events

  • By

  • Olivia Anderson

  • October 21, 2026

  • 3 min

Share

Objective:

To assess the association between antibiotic treatment duration and treatment-related adverse events among female patients with uncomplicated urinary tract infections.

Approach:
  • : A retrospective study used electronic health records from Optum’s de-identified Market Clarity database covering May 2023 through March 2025.
  • : Eligible patients were aged 12 years or older, had symptomatic uncomplicated urinary tract infections, received an antibiotic prescription within 5 days of diagnosis and had at least 12 months of prior electronic health record activity.
  • : Among 57,448 patients, 17,867 (31.1%) received treatment lasting at least 8 days and 39,581 (68.9%) received treatment lasting 5 to 7 days.
  • : Treatment duration was categorized during a 7-day period beginning with the first antibiotic prescription. Treatment-related adverse events were assessed for up to 90 days after that period.
  • : Researchers used propensity score weighting to account for differences in patient characteristics. Findings were presented at IDWeek 2026.
Key Findings:
  • Treatment lasting at least 8 days was associated with a 20% higher overall rate of treatment-related adverse events compared with treatment lasting 5 to 7 days (rate ratio, 1.20; 95% CI, 1.09–1.32; P < 0.001).
  • Extended treatment was associated with higher rates of gastrointestinal events (rate ratio, 1.42; 95% CI, 1.24–1.63), genitourinary events (1.52; 95% CI, 1.25–1.84), endocrine events (1.40; 95% CI, 1.02–1.91) and hypersensitivity events (2.38; 95% CI, 1.28–4.40).
  • Patients receiving extended treatment were older on average, with a mean age of 55.1 years versus 52.3 years, and had more coexisting medical conditions.
  • Nitrofurantoin was the most commonly prescribed antibiotic, accounting for 39% of prescriptions in the extended-treatment group and 46.1% in the 5-to-7-day group.
Interpretation:

The authors associated extended antibiotic treatment with higher treatment-related adverse-event rates and emphasized aligning treatment duration with antimicrobial stewardship guidelines. The findings describe an association rather than establishing that longer treatment caused the events.

Limitations:
  • The retrospective observational design limits causal interpretation. Propensity score weighting accounted for measured patient-characteristic differences but does not establish equivalence between groups.
  • The source article does not provide absolute adverse-event rates, detailed event definitions or results by individual antibiotic.
  • The comparison evaluated courses lasting at least 8 days versus 5 to 7 days; it did not establish an optimal duration for each antibiotic.
  • GSK funded the study. Several authors were GSK employees, some reported stock ownership, and Analysis Group received GSK funding to conduct the study. One co-author also reported research support from Pfizer.
Conclusion:

Among the studied female patients, antibiotic courses lasting at least 8 days were associated with higher rates of treatment-related adverse events than courses lasting 5 to 7 days. The authors highlighted treatment-duration stewardship as a patient-safety priority.

Sources:

Original Source(s)

Related Content